Navigation Links
'Bubble Boy' Kids Living Normally After Gene Therapy: Study
Date:8/24/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Aug. 24 (HealthDay News) -- More than a dozen children with so-called "bubble boy" disease are alive and well, with functioning immune systems, nine years after undergoing gene therapy to correct their disorder, researchers report.

Most of the patients attend school with other children, something that probably would have been fatal without treatment.

"The promise of gene therapy is being fulfilled, at least for these diseases, where a number of patients are walking around in good health because they had gene therapy," said Dr. Donald Kohn, professor of microbiology, immunology and molecular genetics and pediatrics at the University of California, Los Angeles.

The disorder -- severe combined immunodeficiency (SCID) -- compromises the immune system so severely that children can't fight off normally innocuous infections. The condition is rare, and the term "bubble boy" was coined after a Texas boy with the condition lived in a germ-free plastic bubble.

Only boys inherit the gene in question, and many born with SCID die in infancy.

Two studies published Aug. 24 in Science Translational Medicine detail the results of the gene-modifying treatment. Kohn wrote a perspective piece accompanying the studies.

Traditionally, the only treatment for SCID was stem cell transplantation in which immune cells from a matching donor are transferred to the patient. But it's difficult to find matching donors and, even then, the patient's body may reject the transplanted cells.

With gene therapy, clinicians remove the patient's own bone marrow, isolate the stem cells, correct the gene and reinsert it into the patient, explained William J. Bowers, associate professor of neurology at the University of Rochester Medical Center in Rochester, N.Y.

The two current papers detail the success of gene therapy in two groups of patients: 10 boys with X-linked SCID (SCID-X1); and six with ADA-SCID, which involves a slightly different gene mutation. All were between 6 months and 39 months old.

Gene therapy successfully treated four of the six ADA-SCID patients.

All the SCID-X1 children recovered, although one developed leukemia. That boy is currently in remission, but leukemia has been a problem with previous gene therapy trials.

Last year, French researchers reported that eight of nine male infants born with SCID-X1 had recovered as a result of gene therapy. Unfortunately, almost half developed acute leukemia, one of whom died.

The virus vector used in this earlier trial inadvertently activated an oncogene, which led to the development of the leukemia, researchers said.

The latest research circumvented this problem by using a different virus vector.

"A cloud was thrown over the field several years ago and they've solved it nicely," said Dr. Darwin Prockop, director of the Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White in Temple, Texas. "Very probably this can be used for other genetic diseases."

"This field came on with huge promise, then hit a few bumps and now . . . we're starting to see more and more of these successes," added Bowers.

More information

The U.S. National Human Genome Research Institute has more on SCID.

SOURCES: Donald B. Kohn, M.D., professor, microbiology, immunology and molecular genetics and pediatrics, University of California, Los Angeles; William J. Bowers, Ph.D., associate professor, neurology, University of Rochester Medical Center, Rochester, N.Y.; Darwin J. Prockop, M.D., Ph.D., director, Texas A&M Health Science Center College of Medicine Institute for Regenerative Medicine at Scott & White, Temple, Texas; Aug. 24, 2011, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Microbubbles to light the way to sentinel lymph nodes of breast cancer patients
2. Microbubble ultrasound and breast biopsies
3. Bursting bubbles with sound offers new treatments for cancer
4. Baby Bubbler a breath of fresh air
5. Gene Therapy Might Treat Bubble Boy Disease
6. The Acorn Aqua's Lead Free Bubbler
7. The proofs in the bubbles
8. New TB vaccine enters proof-of-concept trial in people living with HIV
9. Minimal scar techniques in living donors for kidney transplant
10. Genes, Not Healthy Living, Get Most to Age 100
11. Americans No Longer Outliving Europeans: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 'Bubble Boy' Kids Living Normally After Gene Therapy: Study
(Date:2/17/2017)... , ... February 17, 2017 , ... ... that allow for the electronic prescribing of controlled and non-controlled substances plus the ... percent of pharmacies in the United States now accept electronic prescriptions, according to ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental ... for each and every seminar, session and class she offers. At the ... tools which help energize creativity, focus mental functions, enhance athletic focus and skill ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today ... Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will ... used electronic patient signatures solution in healthcare . , Since it first ...
(Date:2/17/2017)... Miami, F.L. (PRWEB) , ... February 17, 2017 ... ... geared to clinical operations executives and focusing on all facets of clinical trial ... portfolio management , patient engagement, and more. In addition, attendees stopping by ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for ... Reduction Program (HRRP), the return of a patient to the hospital within 30 days ... many providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017 Quest Diagnostics (NYSE: ... services, today announced that it has been named one ... Fortune. The annual survey designated Quest ... "Health Care: Pharmacy and Other Services" industry to attain ... company to attain the designation. This is the second ...
(Date:2/16/2017)... The global preparative and process chromatography market ... from USD 5.49 billion in 2016, at a CAGR ... type, the preparative and process chromatography market is segmented ... process chromatography segment is expected to account for the ... Growth in this segment can primarily be attributed to ...
(Date:2/16/2017)... Conn. , Feb. 16, 2017 The Lockwood ... the 2017 Best Place to Work in Connecticut ... This is the third year in a row that Lockwood ... this year to earn the number-two spot in 2017. The ... maintaining workplace excellence. The winners were determined through a survey ...
Breaking Medicine Technology: